Patents by Inventor Mary Newman
Mary Newman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220000859Abstract: The present invention provides formulations, methods and kits for the treatment of dry eye diseases. In particular, stabilized pharmaceutical compositions comprising the compound of Formula 1 are described herein for a variety of uses including the treatment of dry eye syndrome. In one aspect, methods and ingredients for improving the stability of compositions of the compound of Formula 1 are described.Type: ApplicationFiled: June 9, 2021Publication date: January 6, 2022Inventors: Mary NEWMAN, William HUNKE
-
Patent number: 11058677Abstract: The present invention provides formulations, methods and kits for the treatment of dry eye diseases. In particular, stabilized pharmaceutical compositions comprising the compound of Formula 1 are described herein for a variety of uses including the treatment of dry eye syndrome. In one aspect, methods and ingredients for improving the stability of compositions of the compound of Formula 1 are described.Type: GrantFiled: December 18, 2013Date of Patent: July 13, 2021Assignee: Novartis AGInventors: Mary Newman, William Hunke
-
Patent number: 10188613Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: GrantFiled: May 3, 2018Date of Patent: January 29, 2019Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Douglas Shytle, Paul R. Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20180250244Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: May 3, 2018Publication date: September 6, 2018Inventors: DOUGLAS SHYTLE, PAUL R. SANBERG, MARY NEWMAN, ARCHIE A. SILVER
-
Publication number: 20170181983Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: March 13, 2017Publication date: June 29, 2017Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: DOUGLAS SHYTLE, PAUL R. SANBERG, MARY NEWMAN
-
Patent number: 9593070Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: GrantFiled: March 12, 2014Date of Patent: March 14, 2017Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20160090361Abstract: The present invention is related to a two-step carboxylation reaction of an aryl group using continuous flow reaction conditions. This process permits large scale synthesis of useful reaction products in high yield.Type: ApplicationFiled: September 25, 2015Publication date: March 31, 2016Inventors: Scott Tweedie, Sripathy Venkatraman, Shuhong Liu, James Zeller, Elisabeth Brot, Michael Hamlin, Mary Newman, Mark McLaws, John Rosenberg, David Lathbury
-
Publication number: 20150320737Abstract: The present invention provides formulations, methods and kits for the treatment of dry eye diseases. In particular, stabilized pharmaceutical compositions comprising the compound of Formula 1 are described herein for a variety of uses including the treatment of dry eye syndrome. In one aspect, methods and ingredients for improving the stability of compositions of the compound of Formula 1 are described.Type: ApplicationFiled: December 18, 2013Publication date: November 12, 2015Inventors: Mary NEWMAN, William HUNKE
-
Publication number: 20140194525Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: March 12, 2014Publication date: July 10, 2014Applicant: Targacept, Inc.Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Patent number: 8026283Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: GrantFiled: January 4, 2010Date of Patent: September 27, 2011Assignee: University of South FloridaInventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20110028565Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: September 21, 2010Publication date: February 3, 2011Applicant: University of South FloridaInventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20100286282Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: January 4, 2010Publication date: November 11, 2010Applicant: Targacept, Inc.Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20060276551Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: April 5, 2006Publication date: December 7, 2006Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie Silver
-
Patent number: 7101916Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: GrantFiled: May 19, 2003Date of Patent: September 5, 2006Assignee: University of South FloridaInventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20060159666Abstract: A method for repairing animal tissue damage due to an inflammatory reaction in an animal has the steps of providing umbilical cord blood cells (UCBCs) in a pharmaceutically acceptable form; and administering a sufficient dose of UCBC at an optimal time thereby reducing the injury from the inflammatory reaction. Also provided are method of treating cerebrovascular accident, acute central nervous inflammation, multiple sclerosis, myocardial ischemia, and neonatal bronchopulmonary distress. For determining the optimal time of UCBCs administration, there is provided a kit containing antibodies for IL-8 and MCP-1.Type: ApplicationFiled: October 24, 2005Publication date: July 20, 2006Inventors: Alison Willing, Paul Sanberg, Mary Newman, Cyndy Sanberg
-
Patent number: 6734215Abstract: Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), Tourette's Syndrome, and neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder).Type: GrantFiled: June 15, 2001Date of Patent: May 11, 2004Assignee: University of South FloridaInventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20040044083Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: September 23, 2003Publication date: March 4, 2004Applicant: University of South FloridaInventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20020016370Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-S-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-S-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: June 15, 2001Publication date: February 7, 2002Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20020016371Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: June 15, 2001Publication date: February 7, 2002Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver